NCT06846437View on ClinicalTrials.gov

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

October 13, 2026

Study Completion Date

December 31, 2028

Conditions
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
Interventions
DRUG

JSKN003

Administered intravenously according to protocol.

DRUG

Trastuzumab emtansine (T-DM1)

Administered intravenously according to the approved label.

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Shanghai JMT-Bio Inc.

INDUSTRY